Recent advancements in emerging technologies, including Generative Artificial Intelligence, have the potential to fundamentally reshape the biotechnology industry.
“We're living through a ‘hinge moment,’ merging tech and biotech to revolutionize drug discovery and development, manufacturing and commercialization,” says David Reese, Amgen’s chief technology officer. “Amgen is focused on accelerating the delivery of new therapies, while simultaneously equipping our employees with access to industry-leading tools to deliver on our mission to serve patients."
Sean Bruich, Amgen’s SVP, Artificial Intelligence and Data, discusses potential impact of OpenAI’s GPT-5.
Amgen was an early adopter of OpenAI’s ChatGPT Enterprise and as capabilities improved, access was scaled across the company. This phased rollout enabled measured testing, supported by security enabling the integration of the technology into meaningful workflows across the enterprise.
As part of Amgen’s strong collaboration with OpenAI and continued commitment to leadership in advancing artificial intelligence applications in the field of biotechnology, Amgen scientists and technologists had the opportunity to assess OpenAI’s latest frontier model, GPT-5.
“Based on our internal evaluation, GPT-5 has shown notable improvements in objective measures like accuracy and reliability, but equally important has been the qualitative feedback from our teams, reporting improvements in output quality,” says Sean Bruich, Amgen’s senior vice president of Artificial Intelligence and Data. “These are critical indicators for a company like Amgen, where maintaining high standards for scientific accuracy and decision quality is essential.”
Each time there is a breakthrough in new capabilities related to OpenAI’s models, it not only has the potential to improve performance in existing workflows but also opens the door to new use cases to explore and test in support of Amgen’s mission to serve patients.
